ALNA - オ―レナ・ファ―マシュ―ティカルズ (Allena Pharmaceuticals Inc.)

ALNAのニュース

   Bright Trending Stock: Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), Rio Tinto Group (NYSE:RIO)  2022/02/23 03:17:40 Stock Equity
Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) with the stream of -5.30% also noticed, India Rio Tinto Group (NYSE:RIO) encountered a rapid change of 0.18% in the last hour of Tuesdays trading session. The post Bright Trending Stock: Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), Rio Tinto Group (NYSE:RIO) appeared first on Stocks Equity .
   Allena Pharmaceuticals Inc Shares Approach 52-Week Low - Market Mover  2022/01/14 05:09:59 Kwhen Finance
Allena Pharmaceuticals Inc (ALNA) shares closed today at 0.4% above its 52 week low of $0.46, giving the company a market cap of $39M. The stock is currently down 19.2% year-to-date, down 65.5% over the past 12 months, and down 95.2% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 58.5% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.6. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 533.5% The company's stock price performance over the past 12 months lags the peer average by 114.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Allena Pharmaceuticals: A Double [Or More] Or Kaput In The Next 90 Days  2022/01/08 05:36:25 Seeking Alpha
   Traders should divert their intention on this Stock: Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), Galiano Gold Inc. (AMEX:GAU)  2021/12/24 04:46:20 Stock Equity
Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) with the stream of -0.41% also noticed, India Galiano Gold Inc. (AMEX:GAU) encountered a rapid change of 0.63% in the last hour of Thursdays trading session. The post Traders should divert their intention on this Stock: Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), Galiano Gold Inc. (AMEX:GAU) appeared first on Stocks Equity .
   Allena Pharmaceuticals (NASDAQ:ALNA) Upgraded by Zacks Investment Research to Buy  2021/12/22 07:46:42 Dakota Financial News
Zacks Investment Research upgraded shares of Allena Pharmaceuticals (NASDAQ:ALNA) from a hold rating to a buy rating in a research report sent to investors on Tuesday, Zacks.com reports. The brokerage currently has $0.75 price target on the stock. According to Zacks, Allena Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in developing and commercializing oral []
   Allena Pharmaceuticals: A Double [Or More] Or Kaput In The Next 90 Days  2022/01/08 05:36:25 Seeking Alpha
   Traders should divert their intention on this Stock: Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), Galiano Gold Inc. (AMEX:GAU)  2021/12/24 04:46:20 Stock Equity
Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) with the stream of -0.41% also noticed, India Galiano Gold Inc. (AMEX:GAU) encountered a rapid change of 0.63% in the last hour of Thursdays trading session. The post Traders should divert their intention on this Stock: Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), Galiano Gold Inc. (AMEX:GAU) appeared first on Stocks Equity .
   Allena Pharmaceuticals (NASDAQ:ALNA) Upgraded by Zacks Investment Research to Buy  2021/12/22 07:46:42 Dakota Financial News
Zacks Investment Research upgraded shares of Allena Pharmaceuticals (NASDAQ:ALNA) from a hold rating to a buy rating in a research report sent to investors on Tuesday, Zacks.com reports. The brokerage currently has $0.75 price target on the stock. According to Zacks, Allena Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in developing and commercializing oral []
   Traders cant Passover this Stock: Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), New Gold Inc. (AMEX:NGD)  2021/12/15 00:14:29 Stock Equity
Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) with the stream of -2.97% also noticed, India New Gold Inc. (AMEX:NGD) encountered a rapid change of -5.56% in the last hour of Tuesdays trading session. The post Traders cant Passover this Stock: Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), New Gold Inc. (AMEX:NGD) appeared first on Stocks Equity .
   State Street Corp Makes New Investment in Allena Pharmaceuticals, Inc. (NASDAQ:ALNA)  2021/12/13 09:10:46 Transcript Daily
State Street Corp bought a new position in shares of Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund bought 34,258 shares of the companys stock, valued at approximately $45,000. State Street Corp owned 0.06% of Allena Pharmaceuticals at the end of []
   Allena Revises Interim Reloxaliase Analysis Targeted Now For Q1 2022; ALLN-346 Phase 2 Data On Track For End Of 2021  2021/07/12 15:07:06 Benzinga
Allena Pharmaceuticals Inc (NASDAQ: ALNA ) provided progress updates on its ALLN-346 and reloxaliase (ALLN-177) clinical programs. ALLN-346 is an enzyme therapy for hyperuricemia and gout, a metabolic disorder characterized by high systemic levels of uric acid. The Company recently completed a Phase 1b multiple ascending dose study. ALLN-346 was well tolerated with no evidence of systemic absorption, and no significant safety signals and serious adverse events were reported. As previously reported, the Company will initiate two Phase Full story available on Benzinga.com
   Allena Pharma provides update on clinical development programs: ALLN-346 and ALLN-177  2021/07/12 13:33:54 Seeking Alpha
   Allena Pharmaceuticals Provides Update on Clinical Development Programs  2021/07/12 12:00:00 Intrado Digital Media
-ALLN-346 successfully completes Phase 1b safety study; on track to start two Phase 2a studies in Q3 2021 with initial data expected in Q4 2021-
   Allena Pharmaceuticals, Inc. to Present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference  2021/07/08 20:17:00 Intrado Digital Media
NEWTON, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that Louis Brenner, M.D., President and Chief Executive Officer, will present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference. Management will also be available for 1x1 meetings on July 13-14, 2021. Details for the presentation are below:
   Traders should follow this: Uber Technologies, Inc. (NYSE:UBER), Allena Pharmaceuticals, Inc. (NASDAQ:ALNA)  2021/07/08 02:16:33 Stock Equity
Uber Technologies, Inc. (NYSE:UBER) with the stream of -3.15% also noticed, India Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) encountered a rapid change of -3.94% in the last hour of Wednesdays trading session. The post Traders should follow this: Uber Technologies, Inc. (NYSE:UBER), Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) appeared first on Stocks Equity .

calendar